HCNP Inhibitors
HCNP inhibitors constitute a diverse group of compounds that play a pivotal role in influencing HCNP, either through direct interaction or indirect modulation of key signaling pathways. While direct inhibitors are limited, several compounds within this class demonstrate efficacy in altering HCNP function by targeting crucial cellular processes. The versatility of these compounds allows researchers to probe the intricate regulatory networks governing HCNP. PI3K inhibitors, namely LY294002 and Wortmannin, disrupt the PI3K/Akt pathway, indirectly impacting HCNP. By interfering with this critical signaling cascade, these inhibitors offer insights into the cross-talk between PI3K/Akt and HCNP-mediated pathways, expanding our understanding of HCNP regulation within cellular contexts. PD98059 and U0126, classified as MEK inhibitors affecting the MAPK pathway, induce alterations in downstream signaling cascades associated with HCNP.
Selective p38 MAPK inhibitors, such as SB203580 and SB590885, modulate HCNP by interfering with the p38 MAPK signaling pathway. By targeting this specific branch of MAPK signaling, these inhibitors offer a targeted approach to understanding the role of HCNP within the broader MAPK network. JNK inhibitors, including SP600125 and SB0102, exert their effects on HCNP by targeting the JNK signaling pathway. Trametinib, identified as a MEK inhibitor, influences HCNP by disrupting the MAPK pathway. The specificity of this inhibitor allows researchers to investigate the nuanced roles of MAPK signaling in the context of HCNP, contributing to a more detailed understanding of HCNP regulation. SB216763, categorized as a GSK-3 inhibitor, and mTOR inhibitors AZD8055 and Rapamycin impact HCNP by targeting the Wnt and mTOR signaling pathways, respectively. Collectively, the compounds within the HCNP inhibitors class form a versatile toolkit for researchers seeking to unravel the intricacies of HCNP biology. These inhibitors provide a foundation for further exploration, enabling a deeper understanding of HCNP modulation and its implications in cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences HCNP by targeting the PI3K/Akt signaling pathway. Inhibition of PI3K by LY294002 disrupts downstream processes involving HCNP, demonstrating its potential to affect HCNP function by modulating the PI3K/Akt-mediated pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly influences HCNP by targeting the PI3K/Akt signaling pathway. Inhibition of PI3K by Wortmannin disrupts downstream processes involving HCNP, demonstrating its potential to affect HCNP function by modulating the PI3K/Akt-mediated pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor affecting the MAPK pathway, indirectly influences HCNP by disrupting the downstream signaling cascade. Through inhibition of MEK, PD98059 alters the MAPK pathway, potentially impacting HCNP function by modulating the pathways associated with MAPK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a selective p38 MAPK inhibitor, indirectly influences HCNP by disrupting the p38 MAPK signaling pathway. Inhibition of p38 MAPK by SB203580 interferes with downstream processes where HCNP is involved, demonstrating its potential to affect HCNP function by modulating the p38 MAPK-mediated pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, indirectly modulates HCNP by targeting the JNK signaling pathway. Inhibition of JNK by SP600125 disrupts downstream processes where HCNP is involved, illustrating its potential to affect HCNP function by influencing the JNK-mediated pathway. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib, a MEK inhibitor affecting the MAPK pathway, indirectly influences HCNP by disrupting the downstream signaling cascade. Through inhibition of MEK, Trametinib alters the MAPK pathway, potentially impacting HCNP function by modulating the pathways associated with MAPK signaling. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763, a GSK-3 inhibitor, indirectly modulates HCNP by targeting the Wnt signaling pathway. Inhibition of GSK-3 by SB216763 disrupts downstream processes involving HCNP, illustrating its potential to affect HCNP function by influencing the Wnt-mediated pathway. | ||||||
SB 590885 | 405554-55-4 | sc-363287 sc-363287A | 10 mg 50 mg | $223.00 $942.00 | ||
SB590885, a selective p38 MAPK inhibitor, indirectly influences HCNP by disrupting the p38 MAPK signaling pathway. Inhibition of p38 MAPK by SB590885 interferes with downstream processes where HCNP is involved, demonstrating its potential to affect HCNP function through the modulation of the p38 MAPK-mediated pathway. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055, a dual mTORC1 and mTORC2 inhibitor, indirectly modulates HCNP by targeting the mTOR signaling pathway. Inhibition of mTOR by AZD8055 disrupts downstream processes where HCNP is involved, demonstrating its potential to affect HCNP function by modulating the mTOR-mediated pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly modulates HCNP by targeting the mTOR signaling pathway. Inhibition of mTOR by Rapamycin disrupts downstream processes where HCNP is involved, demonstrating its potential to affect HCNP function by modulating the mTOR-mediated pathway. | ||||||